Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline

E. Ann Gormley, Deborah J. Lightner, Kathryn L. Burgio, Toby C. Chai, J. Quentin Clemens, Daniel J. Culkin, Anurag Kumar Das, Harris Emilio Foster, Harriette Miles Scarpero, Christopher Tessier, Sandip Prasan Vasavada

Research output: Contribution to journalArticle

333 Citations (Scopus)

Abstract

Purpose: The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of non-neurogenic overactive bladder (OAB). Materials and Methods: The primary source of evidence for this guideline is the systematic review and data extraction conducted as part of the Agency for Healthcare Research and Quality (AHRQ) Evidence Report/Technology Assessment Number 187 titled Treatment of Overactive Bladder in Women (2009). That report searched PubMed, MEDLINE®, EMBASE and CINAHL for English-language studies published from January 1966 to October 2008. The AUA conducted additional literature searches to capture treatments not covered in detail by the AHRQ report and relevant articles published between October 2008 and December 2011. The review yielded an evidence base of 151 treatment articles after application of inclusion/exclusion criteria. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate) or C (low). Additional treatment information is provided as Clinical Principles and Expert Opinions when insufficient evidence existed. Results: The evidence-based guideline statements are provided for diagnosis and overall management of the adult with OAB symptoms as well as for various treatments. The panel identified first through third line treatments as well as non-FDA approved, rarely applicable and treatments that should not be offered. Conclusions: The evidence-based statements are provided for diagnosis and overall management of OAB, as well as for the various treatments. Diagnosis and treatment methodologies can be expected to change as the evidence base grows and as new treatment strategies become obtainable.

Original languageEnglish (US)
Pages (from-to)2455-2463
Number of pages9
JournalJournal of Urology
Volume188
Issue number6 SUPPL.
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Overactive Urinary Bladder
Guidelines
Therapeutics
Health Services Research
Biomedical Technology Assessment
Expert Testimony
PubMed
MEDLINE
Language

Keywords

  • guideline
  • nocturia
  • urinary bladder
  • urinary bladder, overactive
  • urinary incontinence

ASJC Scopus subject areas

  • Urology

Cite this

Gormley, E. A., Lightner, D. J., Burgio, K. L., Chai, T. C., Clemens, J. Q., Culkin, D. J., ... Vasavada, S. P. (2012). Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. Journal of Urology, 188(6 SUPPL.), 2455-2463. https://doi.org/10.1016/j.juro.2012.09.079

Diagnosis and treatment of overactive bladder (non-neurogenic) in adults : AUA/SUFU guideline. / Gormley, E. Ann; Lightner, Deborah J.; Burgio, Kathryn L.; Chai, Toby C.; Clemens, J. Quentin; Culkin, Daniel J.; Das, Anurag Kumar; Foster, Harris Emilio; Scarpero, Harriette Miles; Tessier, Christopher; Vasavada, Sandip Prasan.

In: Journal of Urology, Vol. 188, No. 6 SUPPL., 12.2012, p. 2455-2463.

Research output: Contribution to journalArticle

Gormley, EA, Lightner, DJ, Burgio, KL, Chai, TC, Clemens, JQ, Culkin, DJ, Das, AK, Foster, HE, Scarpero, HM, Tessier, C & Vasavada, SP 2012, 'Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline', Journal of Urology, vol. 188, no. 6 SUPPL., pp. 2455-2463. https://doi.org/10.1016/j.juro.2012.09.079
Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. Journal of Urology. 2012 Dec;188(6 SUPPL.):2455-2463. https://doi.org/10.1016/j.juro.2012.09.079
Gormley, E. Ann ; Lightner, Deborah J. ; Burgio, Kathryn L. ; Chai, Toby C. ; Clemens, J. Quentin ; Culkin, Daniel J. ; Das, Anurag Kumar ; Foster, Harris Emilio ; Scarpero, Harriette Miles ; Tessier, Christopher ; Vasavada, Sandip Prasan. / Diagnosis and treatment of overactive bladder (non-neurogenic) in adults : AUA/SUFU guideline. In: Journal of Urology. 2012 ; Vol. 188, No. 6 SUPPL. pp. 2455-2463.
@article{53270e73170a4d5785382cf54812e9d8,
title = "Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline",
abstract = "Purpose: The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of non-neurogenic overactive bladder (OAB). Materials and Methods: The primary source of evidence for this guideline is the systematic review and data extraction conducted as part of the Agency for Healthcare Research and Quality (AHRQ) Evidence Report/Technology Assessment Number 187 titled Treatment of Overactive Bladder in Women (2009). That report searched PubMed, MEDLINE{\circledR}, EMBASE and CINAHL for English-language studies published from January 1966 to October 2008. The AUA conducted additional literature searches to capture treatments not covered in detail by the AHRQ report and relevant articles published between October 2008 and December 2011. The review yielded an evidence base of 151 treatment articles after application of inclusion/exclusion criteria. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate) or C (low). Additional treatment information is provided as Clinical Principles and Expert Opinions when insufficient evidence existed. Results: The evidence-based guideline statements are provided for diagnosis and overall management of the adult with OAB symptoms as well as for various treatments. The panel identified first through third line treatments as well as non-FDA approved, rarely applicable and treatments that should not be offered. Conclusions: The evidence-based statements are provided for diagnosis and overall management of OAB, as well as for the various treatments. Diagnosis and treatment methodologies can be expected to change as the evidence base grows and as new treatment strategies become obtainable.",
keywords = "guideline, nocturia, urinary bladder, urinary bladder, overactive, urinary incontinence",
author = "Gormley, {E. Ann} and Lightner, {Deborah J.} and Burgio, {Kathryn L.} and Chai, {Toby C.} and Clemens, {J. Quentin} and Culkin, {Daniel J.} and Das, {Anurag Kumar} and Foster, {Harris Emilio} and Scarpero, {Harriette Miles} and Christopher Tessier and Vasavada, {Sandip Prasan}",
year = "2012",
month = "12",
doi = "10.1016/j.juro.2012.09.079",
language = "English (US)",
volume = "188",
pages = "2455--2463",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Diagnosis and treatment of overactive bladder (non-neurogenic) in adults

T2 - AUA/SUFU guideline

AU - Gormley, E. Ann

AU - Lightner, Deborah J.

AU - Burgio, Kathryn L.

AU - Chai, Toby C.

AU - Clemens, J. Quentin

AU - Culkin, Daniel J.

AU - Das, Anurag Kumar

AU - Foster, Harris Emilio

AU - Scarpero, Harriette Miles

AU - Tessier, Christopher

AU - Vasavada, Sandip Prasan

PY - 2012/12

Y1 - 2012/12

N2 - Purpose: The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of non-neurogenic overactive bladder (OAB). Materials and Methods: The primary source of evidence for this guideline is the systematic review and data extraction conducted as part of the Agency for Healthcare Research and Quality (AHRQ) Evidence Report/Technology Assessment Number 187 titled Treatment of Overactive Bladder in Women (2009). That report searched PubMed, MEDLINE®, EMBASE and CINAHL for English-language studies published from January 1966 to October 2008. The AUA conducted additional literature searches to capture treatments not covered in detail by the AHRQ report and relevant articles published between October 2008 and December 2011. The review yielded an evidence base of 151 treatment articles after application of inclusion/exclusion criteria. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate) or C (low). Additional treatment information is provided as Clinical Principles and Expert Opinions when insufficient evidence existed. Results: The evidence-based guideline statements are provided for diagnosis and overall management of the adult with OAB symptoms as well as for various treatments. The panel identified first through third line treatments as well as non-FDA approved, rarely applicable and treatments that should not be offered. Conclusions: The evidence-based statements are provided for diagnosis and overall management of OAB, as well as for the various treatments. Diagnosis and treatment methodologies can be expected to change as the evidence base grows and as new treatment strategies become obtainable.

AB - Purpose: The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of non-neurogenic overactive bladder (OAB). Materials and Methods: The primary source of evidence for this guideline is the systematic review and data extraction conducted as part of the Agency for Healthcare Research and Quality (AHRQ) Evidence Report/Technology Assessment Number 187 titled Treatment of Overactive Bladder in Women (2009). That report searched PubMed, MEDLINE®, EMBASE and CINAHL for English-language studies published from January 1966 to October 2008. The AUA conducted additional literature searches to capture treatments not covered in detail by the AHRQ report and relevant articles published between October 2008 and December 2011. The review yielded an evidence base of 151 treatment articles after application of inclusion/exclusion criteria. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate) or C (low). Additional treatment information is provided as Clinical Principles and Expert Opinions when insufficient evidence existed. Results: The evidence-based guideline statements are provided for diagnosis and overall management of the adult with OAB symptoms as well as for various treatments. The panel identified first through third line treatments as well as non-FDA approved, rarely applicable and treatments that should not be offered. Conclusions: The evidence-based statements are provided for diagnosis and overall management of OAB, as well as for the various treatments. Diagnosis and treatment methodologies can be expected to change as the evidence base grows and as new treatment strategies become obtainable.

KW - guideline

KW - nocturia

KW - urinary bladder

KW - urinary bladder, overactive

KW - urinary incontinence

UR - http://www.scopus.com/inward/record.url?scp=84868700750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868700750&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2012.09.079

DO - 10.1016/j.juro.2012.09.079

M3 - Article

C2 - 23098785

AN - SCOPUS:84868700750

VL - 188

SP - 2455

EP - 2463

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6 SUPPL.

ER -